A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Summary

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Hidradenitis Suppurativa (HS)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Spyre Therapeutics, Inc.

Last updated on ClinicalTrials.gov

October 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites